Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase

Hypertension

Volumn 36, Issue 1, 2000, Pages 97-102

  Yamashita, Tomoya ^a   Kawashima, Seinosuke ^a   Ohashi, Yoshitaka ^a   Ozaki, Masanori ^a   Rikitake, Yoshiyuki ^a   Inoue, Nobutaka ^a   Hirata, Ken Ichi ^a   Akita, Hozuka ^a   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Guanylyl cyclase; Mice, transgenic; Nitric oxide synthase; Protein kinases

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACIC AORTA; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

EID: 0033859852     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.36.1.97     Document Type: Article

References (23)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
2. Moncada S, Higgs EA. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
3. Ignarro L. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1-21.
4. Lincoln TM, Corwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7:328-338.
5. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998;102: 2061-2071.
6. Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Ueyama T, Ishida T, Inoue N, Hirata K, Akita H, Yokoyama M. Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase. Circulation. 2000;101:931-937.
7. Hirata K, Kuroda R, Sakoda T, Katayama M, Inoue N, Suematsu M, Kawashima S, Yokoyama M. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension. 1995;25:180-185.
8. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular Superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross tolerance. J Clin Invest. 1995;95:187-194.
9. Axelsson KL, Andersson RGG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983;88:71-79.
10. Diwan AH, Thompson WJ. Lee AK, Strada SJ. Cyclic GMP-dependent protein kinase activity in rat pulmonary microvascular endothelial cells. Biochem Biophys Res Commun. 1994;202:728-735.
11. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520-531.
12. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709-715.
13. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol. 1986;35:3525-3531.
14. Silver PJ, Pagani ED, de Garavilla L, VanAller GS, Volberg ML, Pratt PF, Buchholz RA. Reversal of nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast. Eur J Pharmacol. 1991;199: 141-142.
15. Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitrate tolerance, Proc Natl Acad Sci U S A. 1995;92:5224-5248.
16. Moncada S, Rees DD, Schulz R, Palmer RMJ. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A. 1991;88:2166-2170.
17. Faraci FM, Sigmund CD, Shesely EG, Maeda N, Heistad DD. Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase. Am J Physiol. 1998;274:H564-H570.
18. Matsumoto T, Okamura T, Kinoshita M, Toda N. Interactions of nitrovasodilators and atrial natriuretic peptide in isolated dog coronary arteries. Eur J Pharmacol. 1993;237:31-37.
19. Soff GA, Cornwell TL, Cundiff DL, Gately S, Lincoln TM. Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest. 1997;100:2580-2587.
20. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory response to continuous and intermittent therapy with nitroglycerin. Circulation. 1991;84:2336-2345.
21. Ooboshi H, Chu Y, Rios CD, Faraci FM, Davidson BL, Heistad DD. Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase. Am J Physiol. 1997;273:H265-H270.
22. Kullo IJ, Mozes G, Schwartz RS, Gloviczki P, Crotty TB, Barber DA, Katusic ZS, O'Brien T. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation. 1997;96:2254-2261.
23. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.